Jinling Pharmaceutical (000919.SZ): Termination of Intent to Acquire Equity in Sihao Company

Jinling Pharmaceutical (000919.SZ) announced that on April 13, 2026, the company submitted a "Letter of Investment Intent" to Changzhou Sihao Pharmaceutical Co., Ltd. ("Sihao Company"), indicating that the company and/or entities controlled with the company's participation intended to acquire, in cash, 100% of the equity of Sihao Company held by its current shareholders. Since submitting the "Letter of Investment Intent" to Sihao Company on April 13, 2026, the company has carried out due diligence, preliminary audit and asset valuation, and transaction scheme assessment in an orderly manner, and has maintained continuous communication and negotiation with relevant parties regarding the investment intent. Recently, the company received an "Invitation Letter" issued by Sihao Factory, under which 100% of the equity of Sihao Company and certain land and plant assets of Sihao Factory are proposed to be sold by way of bidding. Based on the "Invitation Letter" and the accompanying "Bidding Operation Guidelines" and other materials received by the company, and in light of information learned earlier, after prudent study, the company has decided not to participate in this bidding activity and to terminate the aforementioned investment intent.